GlassScriptPhysician profile
Elise Barrett
NPI 1871733121
$955.23
in general payments reported to CMS, 2019-2025
23 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.97 · 2022: $119 · 2023: $264 · 2024: $71.69 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $815.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $122.00 | 2025 | Korlym |
| Exact Sciences Corporation | $111.45 | 2023-2025 | Cologuard Collection Kit |
| Organon LLC | $91.81 | 2022-2023 | Nexplanon |
| Abbvie INC. | $69.44 | 2023-2024 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $65.08 | 2023-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $65.00 | 2023-2025 | Fasenra, Airsupra, Farxiga |
| Lilly USA, LLC | $52.39 | 2025 | Mounjaro, Zepbound |
| Ethicon INC. | $37.92 | 2023 | Monarch Platform |
| Abiomed | $34.73 | 2025 | |
| Neurocrine Biosciences, INC. | $34.45 | 2025 | |
| Viatris Specialty LLC | $34.02 | 2025 | Yupelri |
| Madrigal Pharmaceuticals | $30.00 | 2025 | Rezdiffra |
| Dexcom, INC. | $24.79 | 2022 | |
| Lucid Diagnostics INC. | $22.58 | 2023 | |
| Abbott Laboratories | $21.16 | 2025 | Freestyle Libre 3 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $21.08 | 2025 | Inspire |
| Seqirus USA INC | $20.97 | 2019 | |
| Bavarian Nordic A/S | $17.81 | 2025 | Vivotif |
| Hologic Sales and Service, LLC | $17.51 | 2023 | Aptima |
| Glaxosmithkline, LLC. | $16.40 | 2025 | Trelegy Ellipta |
| Viiv Healthcare Company | $16.19 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.34 | 2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $13.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elise Barrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.